RxDoctor Payments Data

Bassem Nasser, MD

Cardiovascular Disease · Fall River, MANPI 1881692952

Payments from drug & device makers

$16,055in general payments, 2019–2025

Across 917 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$2K
  • Boston Scientific$2K
  • Novartis$2K
  • Amgen$1K
  • Pfizer$995
  • Johnson & Johnson$910
  • plus $7K from 27 others

What the payments were for

  • Food & beverage$15,81599%
  • Education$2401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,055 in reported general payments places this provider in the 70th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$456,571
Medicare patients
1,226
Services billed
5,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,048$902,108
EntrestoSacubitril/Valsartan366$387,202
XareltoRivaroxaban151$108,959
Repatha SureclickEvolocumab118$103,875
BrilintaTicagrelor65$50,825
FarxigaDapagliflozin Propanediol36$35,814
Metoprolol Succinate979$17,580
Praluent PenAlirocumab26$16,063
VascepaIcosapent Ethyl29$13,185
CorlanorIvabradine Hcl12$11,306
Pitavastatin Calcium21$10,431
LivaloPitavastatin Calcium13$9,945
Prasugrel Hcl72$6,845
Atorvastatin Calcium500$6,198
Ranolazine ErRanolazine46$5,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$995$902,1081,048 claims
NovartisEntresto$1,837$387,202366 claims
Johnson & JohnsonXarelto$910$108,959151 claims
AstraZenecaBrilinta, Farxiga$425$86,639101 claims
AmgenCorlanor$1,037$11,30612 claims
Kowa Pharmaceuticals America, Inc.Livalo$435$9,94513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Fall River

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →